SCHEMBL6285728

SCHEMBL6285728

N#C/C(=C\c1cc(O)ccc1O)C(N)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 7/20 1.00
LCK P06239 2/20 1.00
KDM4E B2RXH2 5/20 0.60
CYP1A2 P05177 4/20 0.60
MAPT P10636 3/20 0.60
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
TDP1 Q9NUW8 2/20 0.60
ALDH1A1 P00352 1/20 0.60
ERBB2 P04626 1/20 0.60
TP53 P04637 1/20 0.60
HPGD P15428 1/20 0.60
HSD17B10 Q99714 1/20 0.60
POLB P06746 1/20 0.55
GAA P10253 1/20 0.55
APEX1 P27695 1/20 0.55
BLM P54132 1/20 0.55
MCL1 Q07820 1/20 0.50
CYP2C9 P11712 2/20 0.49
CYP3A4 P08684 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6285724 1.00 EGFR (1.00) EGFRLCKKDM4ECYP1A2MAPT
SCHEMBL6285718 1.00 EGFR (1.00) EGFRLCKKDM4ECYP1A2MAPT
SCHEMBL8749032 0.85 EGFR (1.00) EGFRLCKKDM4EMEN1KMT2A
SCHEMBL8743707 0.85 EGFR (1.00) EGFRLCKKDM4EMEN1KMT2A
SCHEMBL8830586 0.79 EGFR (0.66) EGFRLCKKDM4ECYP1A2MAPT
SCHEMBL8830416 0.79 EGFR (0.66) EGFRLCKKDM4ECYP1A2MAPT
SCHEMBL9539321 0.76 KDM4E (0.71) EGFRLCKKDM4ECYP1A2MAPT
SCHEMBL9539318 0.76 KDM4E (0.71) EGFRLCKKDM4ECYP1A2MAPT
SCHEMBL7456830 0.76 EGFR (0.60) EGFRLCKKDM4ECYP1A2MAPT
SCHEMBL7456833 0.76 EGFR (0.60) EGFRLCKKDM4ECYP1A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE38761-E1 Styryl compounds which inhibit EGF receptor protein tyrosine kinase YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2005-07-19 US disclosed
EP-0788358-B1 USE OF PYRAZOLE COMPOUNDS FOR THE TREATMENT OF GLOMERULONEPHRITIS, CANCER, ATHEROSCLEROSIS OR RESTENOSIS MILLENNIUM PHARM INC (US) 2004-03-31 EP disclosed
EP-0788356-B9 METHOD AND COMPOSITIONS FOR INHIBITING PROTEIN KINASES COR THERAPEUTICS INC (US) 2002-10-02 EP disclosed
EP-0788356-B1 METHOD AND COMPOSITIONS FOR INHIBITING PROTEIN KINASES COR THERAPEUTICS INC (US) 2001-12-12 EP disclosed
US-5916908-A Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases COR THERAPEUTICS, INC. (US) 1999-06-29 US disclosed
US-5795910-A Method and compositions for inhibiting protein kinases COR THERAPEUTICS, INC. (US) 1998-08-18 US disclosed
US-5728726-A Method and compositions for inhibiting protein kinases COR THERAPEUTICS, INC. (US) 1998-03-17 US disclosed
US-5674892-A CONTACTING WITH BENZOXACYCLOTETRADECIN DERIVATIVES COR THERAPEUTICS, INC. (US) 1997-10-07 US disclosed
EP-0788358-A2 PHARMACEUTICAL PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES COR THERAPEUTICS, INC. (US) 1997-08-13 EP disclosed
EP-0788356-A2 METHOD AND COMPOSITIONS FOR INHIBITING PROTEIN KINASES COR THERAPEUTICS, INC. (US) 1997-08-13 EP disclosed
WO-1996014843-A2 PHARMACEUTICAL PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES COR THERAPEUTICS, INC. (US) 1996-05-23 WO disclosed
WO-1996013259-A2 METHOD AND COMPOSITIONS FOR INHIBITING PROTEIN KINASES COR THERAPEUTICS, INC. (US) 1996-05-09 WO disclosed
US-5217999-A Antigrowth agents YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1993-06-08 US disclosed
WO-1991016892-A1 STYRYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR PROTEIN TYROSINE KINASE RORER INTERNATIONAL (HOLDINGS), INC. (US) 1991-11-14 WO disclosed